2026-01-02 - Analysis Report
Okay, here's a breakdown of the Johnson & Johnson (JNJ) stock data, presented with simple numbers first, followed by analysis:

**1. Return Rate Comparison:**

*   **JNJ Cumulative Return:** 52.50%
*   **S&P 500 (VOO) Cumulative Return:** 91.40%
*   **Divergence:** -52.6
*   **Relative Divergence:** 27.1

**Analysis:**

*   Johnson & Johnson (JNJ) is a diversified healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.
*   JNJ has significantly underperformed the S&P 500 over the tracked period. The divergence of -52.6 indicates a substantial difference in cumulative returns.
*   The relative divergence of 27.1 suggests that the current divergence is closer to the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 6.0% | 99.8% | 3.0% | 0.7 | 310.9 |
| 2017-2019  | 18.0% | 94.9% | 1.0% | 0.7 | 351.4 |
| 2018-2020  | 19.0% | 92.7% | -2.0% | 0.7 | 379.2 |
| 2019-2021  | 32.0% | 78.7% | -12.0% | 0.6 | 412.2 |
| 2020-2022  | 8.0% | 64.1% | 10.0% | 0.5 | 425.6 |
| 2021-2023  | -18.0% | 73.5% | -19.0% | 0.3 | 377.6 |
| 2022-2024  | -30.0% | 82.0% | -50.0% | 0.2 | 348.4 |
| 2023-2025  | 30.0% | 79.5% | -32.0% | 0.1 | 498.6 |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows fluctuating performance, with significant negative returns in 2021-2023 and 2022-2024. The most recent period (2023-2025) shows a strong recovery.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant potential for loss during the periods.
*   **Alpha:** Alpha is mostly negative, suggesting underperformance compared to a benchmark (likely the S&P 500). It is very negative in the most recent periods, indicating significant underperformance.
*   **Beta:** Beta is consistently below 1, suggesting lower volatility than the market. It has been decreasing over time.
*   **Cap(B):** Market capitalization has generally increased, with a recent surge, showing investor confidence.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** $206.95
*   **Previous Close:** $206.91
*   **Change:** $0.02
*   **5-day SMA:** 207.37
*   **20-day SMA:** 206.89
*   **60-day SMA:** 198.45

**Analysis:**

*   The stock price is slightly up from the previous close.
*   The 5-day SMA is above the 20-day SMA, suggesting a short-term upward trend.
*   Both the 5-day and 20-day SMAs are above the 60-day SMA, indicating that the stock price has been trending upward over the past two months.

**3. Index Indicators & Expected Return:**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 50.90
*   **PPO:** -0.35
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)
*   **Recent Relative Divergence Change:** 3.2 (+) (Short-term increase)
*   **Expected Return:** 0.0%

**Analysis:**

*   The MRI suggests a high investment recommendation, potentially driven by factors beyond the stock's direct performance (e.g., sector outlook).
*   RSI is near 50, indicating a neutral momentum.
*   PPO is slightly negative, suggesting a minor downward trend in price momentum.
*   The Hybrid Signal advises a cautious buy, allocating 80% of available cash and buying 2 shares due to an MRI of 0.7.
*   The recent increase in relative divergence suggests a recent improvement in JNJ's performance compared to its comparison.
*   The expected return is 0%, suggesting that analysts do not expect JNJ to outperform the market in the long term.

**4. Recent News & Significant Events:**

*   The news headlines are mixed. Some articles discuss upside potential for JNJ in 2026 and institutional investors increasing their stakes.
*   Other articles mention JNJ's 2025 surge, a cancer deal, and Barclays lifting its target price, alongside a discussion of cash flow and earnings.
*   A MarketBeat article reports Johnson & Johnson shares being purchased by Ethic Inc.
*   One article also mentions JNJ slipping after a $3.05B cancer deal, indicating some uncertainty around the deal's impact.

**Analysis:**

*   The news reflects a combination of positive and cautious sentiment surrounding JNJ.
*   The coverage on institutional investors increasing their stakes is a positive sign.
*   The discussion of cash flow and earnings suggests scrutiny of the company's financial performance.
*   The coverage of the Halda cancer deal reveals the risk of specific deals being evaluated by investors.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** $210.13 (Avg), $240.00 (High), $155.00 (Low)
*   **Recent Rating Changes:** Not Available

**Analysis:**

*   The analyst consensus is "Buy," indicating a generally positive outlook on the stock.
*   The average target price of $210.13 is slightly above the current price, suggesting a potential upside.
*   The range of target prices is wide ($155 to $240), indicating some disagreement among analysts about the stock's future performance.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-22 | 2.14 | 23.99 B$  |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2025-10-22 | 1.12 | 22.47 B$  |

**Analysis:**

*   EPS (Earnings Per Share) has fluctuated significantly, with the highest value in 2025-04-23.
*   Revenue has been relatively stable, with some quarter-to-quarter variations.
*   The repeating date suggests there is a typo in the table. Assuming the last item should be 2024-07-24, EPS would show a relatively upward trend until 2025-04-23.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B    | 69.56%        |
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |

**Analysis:**

*   Revenue has shown a general upward trend over the past five quarters.
*   Profit margins have remained consistently high, indicating strong profitability for JNJ.

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $79.28B    | 6.50%  |
| 2025-06-30   | $78.47B    | 7.06%  |
| 2025-03-31   | $78.11B    | 14.08% |
| 2024-12-31   | $71.49B    | 4.80%  |
| 2024-09-30   | $70.16B    | 3.84%  |

**Analysis:**

*   Equity has been steadily increasing, reflecting growth in the company's net worth.
*   ROE (Return on Equity) has fluctuated, with a high in 2025-03-31, indicating varying levels of profitability relative to shareholder equity.

**7. Comprehensive Analysis:**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the tracked period.
*   **Mixed Signals:** Technical indicators and news headlines provide mixed signals, with positive analyst ratings and institutional investment offset by concerns about underperformance and specific business deals.
*   **Financial Strength:** JNJ's financials are generally strong, with increasing revenue, high profit margins, and growing equity. However, ROE has fluctuated.
*   **Cautious Optimism:** While the MRI suggests high investment recommendation, the hybrid signal and the cautious buy, reflecting some risk aversion given the underperformance issue.
* **News Momentum:** The recent news points to a potential positive momentum, with new investments and optimistic forecasts, but this is balanced by news articles highlighting concerns and price drops.

**Overall Recommendation:**

The data suggests a mixed picture. While JNJ exhibits financial strength and analyst optimism, the underperformance compared to the S&P 500 is a significant concern. The investment decision should consider the investor's risk tolerance and investment horizon. Cautious buying might be a starting strategy. More thorough investigation is recommended.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.